Germany's Merck KGaA said it is in advanced talks for a potential acquisition of SpringWorks Therapeutics, a U.S. biopharmaceutical company that specializes in rare diseases and cancer.

Merck KGaA is in advanced talks to acquire SpringWorks Therapeutics, aiming to expand its cancer treatment pipeline. While no binding agreement exists yet, a potential deal is seen as strategically ...

SpringWorks Therapeutics stock surged over Monday after a report from Reuters that German medical tech giant Merck KGaA could be close to acquiring the company.

As SpringWorks Therapeutics nears a key regulatory decision in the U.S., the Connecticut-based cancer and rare disease ...

German healthcare giant Merck KGaA is in advanced talks to acquire U.S.-based Springworks Therapeutics, known for cancer and rare disease treatments. The potential acquisition would enhance Merck's ...

Report with market evolution powered by AI - The global antibiotics market size is estimated to grow by USD 18.22 billion ...

Now that the year is underway and a new presidential administration is in place in Washington, let’s consider the environment ...

Investors hammered Merck stock Tuesday after the company beat fourth-quarter expectations, but delivered a light 2025 outlook.

Subin Baral, EY global life sciences deals leader, told GEN M&A deals are expected to increase in 2025, driven by biopharmas that are eager to recoup revenues they expect to lose as their aging ...

We recently published a list of Top 10 Best Dividend Stocks on Robinhood. In this article, we are going to take a look at ...

Merck (NSE:PROR) & Co., Inc. (NYSE ... network via organic expansions and acquisitions and has been on a mergers and acquisitions (M&A) binge in recent years. In 2023, it bought Magellan Midstream ...

According to the release, an overwhelming majority of shareholders were in favour of the merger. Myer reported that 96.16% of votes were approved the combination, with only 3.84% voting against it.